Hepatitis B core-based virus-like particles: A platform for vaccine development in plants

Vahdat, Maryam Moradi; Hemmati-Dinarvand, Mohsen; Ghorbani, Abozar; Rutkowska, Daria; Afsharifar, Alireza; Eskandari, Mohammad Hadi; Rezaei, Nahid; Niazi‎, Ali

doi:10.1016/j.btre.2021.e00605

Cited by 29 publications

(32 citation statements)

References 194 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are numerous examples of plant viruses used including tobacco mosaic virus (TMV), cowpea mosaic virus (CPMV) and potato virus X (PVX) [ 19 , 44 ]. HBV core and surface antigens have been fairly widely used as carriers for immunogenic epitopes on HBV particles assembled in plants [ 45 ]. A more recent development to overcome the crowding effect of displayed antigens/epitopes is Tandem Core Technology [ 46 ].…”

Section: Types Of Plant-produced Vaccinesmentioning

confidence: 99%

Plant-Derived Human Vaccines: Recent Developments

2022

View full text Add to dashboard Cite

The idea of producing vaccines in plants originated in the late 1980s. Initially, it was contemplated that this notion could facilitate the concept of edible vaccines, making them more cost effective and easily accessible. Initial studies on edible vaccines focussed on the use of a variety of different transgenic plant host species for the production of vaccine antigens. However, adequate expression levels of antigens, the difficulties predicted with administration of consistent doses, and regulatory rules required for growth of transgenic plants gave way to the development of vaccine candidates that could be purified and administered parenterally. The field has subsequently advanced with improved expression techniques including a shift from using transgenic to transient expression of antigens, refinement of purification protocols, a deeper understanding of the biological processes and a wealth of evidence of immunogenicity and efficacy of plant-produced vaccine candidates, all contributing to the successful practice of what is now known as biopharming or plant molecular farming. The establishment of this technology has resulted in the development of many different types of vaccine candidates including subunit vaccines and various different types of nanoparticle vaccines targeting a wide variety of bacterial and viral diseases. This has brought further acceptance of plants as a suitable platform for vaccine production and in this review, we discuss the most recent advances in the production of vaccines in plants for human use.

show abstract

Section: Types Of Plant-produced Vaccinesmentioning

confidence: 99%

Plant-Derived Human Vaccines: Recent Developments

2022

View full text Add to dashboard Cite

show abstract

“…Alternative approaches for the assembly of VLPs are also being investigated, including the development of “hybrid” VLPs, which use the core of one virus as a scaffold for the surface glycoproteins of another virus. Hepatitis B cores (HBc) are one example of this, where the HBc structure has been used as a VLP core to present surface antigens from heterologous viruses including HIV, foot and mouth disease virus, and influenza A (reviewed in [ 31 ]). Such hybrid VLPs may offer a universal platform for VLP production and have the advantage of producing non-enveloped particles, which are inherently more stable than enveloped VLPs [ 32 ].…”

Section: Overview Of Vaccines For Ai and Nd Immunisationmentioning

confidence: 99%

Development of Plant-Based Vaccines for Prevention of Avian Influenza and Newcastle Disease in Poultry

et al. 2022

View full text Add to dashboard Cite

Viral diseases, including avian influenza (AI) and Newcastle disease (ND), are an important cause of morbidity and mortality in poultry, resulting in significant economic losses. Despite the availability of commercial vaccines for the major viral diseases of poultry, these diseases continue to pose a significant risk to global food security. There are multiple factors for this: vaccine costs may be prohibitive, cold chain storage for attenuated live-virus vaccines may not be achievable, and commercial vaccines may protect poorly against local emerging strains. The development of transient gene expression systems in plants provides a versatile and robust tool to generate a high yield of recombinant proteins with superior speed while managing to achieve cost-efficient production. Plant-derived vaccines offer good stability and safety these include both subunit and virus-like particle (VLP) vaccines. VLPs offer potential benefits compared to currently available traditional vaccines, including significant reductions in virus shedding and the ability to differentiate between infected and vaccinated birds (DIVA). This review discusses the current state of plant-based vaccines for prevention of the AI and ND in poultry, challenges in their development, and potential for expanding their use in low- and middle-income countries.

show abstract

“…Many reports explain the role of NPs in SARS-CoV-2 in detail [136][137][138][139][140][141][142]. For the production of VLPs, several studies target Poliovirus, hepatitis B virus, human papillomavirus, influenza virus, Norwalk virus, human immunodeficiency retrovirus 1, rift valley fever virus, and foot and mouth disease virus [132,[146][147][148][149][150][151][152][153][154][155][156][157][158]. Earlier experience of forming VLPs for MERS and SARS-CoV-1 antigens heterologous expressed in recombinant systems provides us the best platform for developing a vaccine against SARS-CoV-2.…”

Section: Scope Of Sars-cov-2 Vaccine Development Using Plant Biotechnology Platformmentioning

confidence: 99%

A Comprehensive Overview on the Production of Vaccines in Plant-Based Expression Systems and the Scope of Plant Biotechnology to Combat against SARS-CoV-2 Virus Pandemics

Kumar

Kumari

Thakur

et al. 2021

Plants

View full text Add to dashboard Cite

Many pathogenic viral pandemics have caused threats to global health; the COVID-19 pandemic is the latest. Its transmission is growing exponentially all around the globe, putting constraints on the health system worldwide. A novel coronavirus, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), causes this pandemic. Many candidate vaccines are available at this time for COVID-19, and there is a massive international race underway to procure as many vaccines as possible for each country. However, due to heavy global demand, there are strains in global vaccine production. The use of a plant biotechnology-based expression system for vaccine production also represents one part of this international effort, which is to develop plant-based heterologous expression systems, virus-like particles (VLPs)-vaccines, antiviral drugs, and a rapid supply of antigen-antibodies for detecting kits and plant origin bioactive compounds that boost the immunity and provide tolerance to fight against the virus infection. This review will look at the plant biotechnology platform that can provide the best fight against this global pandemic.

show abstract

Hepatitis B core-based virus-like particles: A platform for vaccine development in plants

Cited by 29 publications

References 194 publications

Plant-Derived Human Vaccines: Recent Developments

Plant-Derived Human Vaccines: Recent Developments

Development of Plant-Based Vaccines for Prevention of Avian Influenza and Newcastle Disease in Poultry

A Comprehensive Overview on the Production of Vaccines in Plant-Based Expression Systems and the Scope of Plant Biotechnology to Combat against SARS-CoV-2 Virus Pandemics

Contact Info

Product

Resources

About